EGFR and neoplasm: For example, the discordance of KRAS and BRAF mutations due to genetic diversification of metastatic cells compared to their primary tumor, may explain the lack of efficacy and the emergence of subsequent resistance when treating metastatic disease with EGFR monoclonal antibodies.